Transgenic Mouse Model for Mood Disorders Using Thy1 Promoter
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models for psychiatric disorders like major depression and anxiety are inadequate for effectively evaluating the efficacy of therapeutic compounds due to the complexity of these disorders, making it difficult to predict whether genetic alterations associated with the disorders will produce relevant behavioral changes.
Innovation Solution
Development of transgenic rodents with altered pleiotrophin (PTN) expression in the brain using neuron-specific promoters, such as the Thy1 promoter, to mimic depressive and anxious behaviors, allowing for the evaluation of therapeutic agents and understanding of psychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgenic rodents with altered PTN expression are developed to model psychiatric disorders, then the accuracy of the animal model for predicting therapeutic efficacy is improved, but the complexity of the model system increases
Solution Approach 1:
The patent applies local quality by using neuron-specific promoters (such as Thy1 promoter) to drive PTN expression specifically in neuronal tissues of the brain rather than throughout the entire organism. This localized expression strategy increases model accuracy for psychiatric disorders while minimizing off-target effects and reducing overall system complexity compared to constitutive expression models.
2Reliability
If multiple genetic alterations are introduced to model the polygenic nature of psychiatric disorders, then the biological validity of the model is improved, but the difficulty of model development and characterization increases
Solution Approach 1:
The patent employs segmentation by focusing on single-gene or single-pathway models (PTN expression) rather than attempting to model all genetic factors simultaneously. This segmented approach allows for systematic characterization of individual genetic contributions to psychiatric phenotypes, making the models more manageable and easier to develop while still providing biologically valid insights into specific molecular pathways.
3Ease of manufacture
If constitutive expression of PTN is used in transgenic models, then the ease of model creation is improved, but the specificity of the model for psychiatric disorders decreases
Solution Approach 1:
The patent uses neuron-specific promoters to achieve localized PTN expression in neuronal tissues, which increases the specificity of the model for psychiatric disorders. This approach maintains relative ease of model creation through standard transgenic techniques while ensuring that PTN overexpression occurs only in the relevant brain regions associated with mood and anxiety disorders, rather than throughout the entire organism.
Data Source
AI summary
A non-human transgenic animal having a polynucleotide encoding a PTN polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the PTN polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illnesses, particularly anxiety and depression, are disclosed.